Sphingomyelin Synthase 2 Activity and Liver Steatosis
An Effect of Ceramide-Mediated Peroxisome Proliferator-Activated Receptor γ2 Suppression

Yue Li,* Jibin Dong,* Tingbo Ding,* Ming-Shang Kuo, Guoqing Cao, Xian-Cheng Jiang, Zhiqiang Li

Objective—Sphingolipid de novo biosynthesis is related to nonalcoholic fatty liver disease or hepatic steatosis. However, the mechanism is still unclear. Sphingomyelin synthase (SMS), using ceramide as one of the substrates to produce sphingomyelin, sits at the crossroads of sphingolipid biosynthesis. SMS has 2 isoforms: SMS1 and SMS2. SMS2 is the major isoform in liver.

Approach and Results—To investigate the relationship between liver SMS activity–mediated sphingolipid changes and hepatic steatosis, we used 2 mouse models: Sms2 liver-specific transgenic and Sms2 knockout mice. We found that Sms2 liver-specific transgenic livers have lower ceramide and higher sphingomyelin, whereas Sms2 knockout livers have higher ceramide and lower sphingomyelin. We also found that liver Sms2 overexpression promoted fatty acid uptake and liver steatosis, whereas Sms2 deficiency had an opposite effect in comparison with their respective controls. Importantly, the exogenous ceramide supplementation to Huh7 cells, a human hepatoma cell line, reduced the expression of peroxisome proliferator-activated receptor γ2 and its target genes, Cd36 and Fsp27. Peroxisome proliferator-activated receptor γ reporter analysis confirmed this phenomenon. Furthermore, peroxisome proliferator-activated receptor γ antagonist treatment significantly decreased triglyceride accumulation in Sms2 liver-specific transgenic liver.

Conclusions—We attributed these effects to ceramide that can suppress peroxisome proliferator-activated receptor γ2, thus reducing the expression of Cd36 and Fsp27 and reducing liver steatosis. After all, SMS2 inhibition in the liver could diminish liver steatosis. (Arterioscler Thromb Vasc Biol. 2013;33:1513-1520.)

Key Words: CD36 ■ ceramide ■ liver lipids ■ liver steatosis ■ peroxisome proliferator-activated receptor γ2 ■ sphingolipids ■ sphingomyelin

There is a relationship between sphingolipid de novo biosynthesis and nonalcoholic fatty liver disease or hepatic steatosis.1 However, the mechanism is still unclear because many sphingolipids may be involved in fatty liver formation. Sphingomyelin synthase (SMS), which uses ceramide as one of the substrates to produce sphingomyelin, sits at the crossroads of sphingolipid biosynthesis. Overexpression or blockage of SMS activity should influence not only sphingomyelin but also ceramide levels.2 SMS has 2 isoforms: SMS1 and SMS2. The major isoform in the liver is SMS2.2,3 Ceramide is composed of sphingosine and a fatty acid. Ceramide can be generated through the de novo pathway.4 It also can be generated through the sphingomyelinase pathway, which breaks down sphingomyelin in the cell membranes and releases ceramide.5 Roles have been proposed for ceramide in heart disease, and it has been shown to induce apoptosis.6 Ceramide mediates an inflammatory response initiated by cytokines or oxidized low-density lipoprotein, a response that upregulates adhesion molecule expression and induces adhesion and migration of monocytes. These events are crucial in the initiation and progression of atherogenesis.7,8 Plasma ceramide may contribute to maladaptive inflammation in patients with coronary heart disease.9 It has been reported that plasma ceramide levels in apolipoprotein E knockout (KO) mice are higher than in controls.10 Plasma ceramides may also correlate with oxidized low-density lipoprotein, becoming a risk factor for atherosclerosis.10

CD36 is a member of the class B scavenger receptor family, located on cell surface lipid rafts.11 CD36 expression is increased concomitantly with hepatic TG content in different animal models of liver steatosis.12,23 CD36 is regulated by peroxisome proliferator-activated receptor (PPAR) γ.14 PPARγ and Cd36 mRNA expression is specifically upregulated in high-fat diet–induced liver steatosis in mice.15

PPARγ is a member of a nuclear hormone superfamily that heterodimerizes with the retinoid X receptor. These
proteins are transcriptional regulators of genes encoding proteins involved in adipogenesis and lipid metabolism. PPARγ exists in 3 protein isoforms, PPARγ1, PPARγ2, and PPARγ3, which are created by alternative promoter usage and alternative splicing at the 5’ end of the gene. PPARγ3 expression was restricted to colon and adipose tissue in humans. PPARγ2 contains 30 additional amino acids at the N terminus compared with PPARγ1. PPARγ1 is expressed in many tissues, whereas significant PPARγ2 expression is limited in certain tissues, such as adipose tissues and the liver. Increased expression of either or both isoforms has been observed in livers of obese and insulin-resistant rodents. In fact, aberrant hepatic expression of PPARγ3 stimulates hepatic lipogenesis in a mouse model dealing with obesity, insulin resistance, dyslipidemia, and hepatic steatosis.

In this study, we specifically investigated diet-induced liver steatosis in both liver-specific Sms2 transgenic and Sms2 KO mice. We found that liver Sms2 overexpression promotes mouse liver steatosis, whereas Sms2 deficiency has opposite effect in comparison with controls. We explored the potential mechanisms in this study.

Materials and Methods

Materials and Methods are available in the online-only Supplement.

Table 1. Mouse Liver Lipid Measurement in Sms2 KO, Sms2LTg, and WT Mice

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>Sms2LTg</th>
<th>WT</th>
<th>Sms2KO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chow diet</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol, μg/mg liver</td>
<td>1.0±0.1</td>
<td>1.2±0.6</td>
<td>0.8±0.2</td>
<td>0.7±0.1</td>
</tr>
<tr>
<td>Phospholipids, μg/mg liver</td>
<td>2.7±0.3</td>
<td>3.2±0.4</td>
<td>2.9±0.3</td>
<td>2.7±0.2</td>
</tr>
<tr>
<td>Triglyceride, μg/mg liver</td>
<td>10±2</td>
<td>15±3*</td>
<td>11±3</td>
<td>9±2</td>
</tr>
<tr>
<td>FFA, μmol/mg liver</td>
<td>7.1±0.6</td>
<td>8.5±0.4</td>
<td>7.9±1.1</td>
<td>6.5±0.3*</td>
</tr>
<tr>
<td>Sphingomyelin, μg/mg liver</td>
<td>0.8±0.2</td>
<td>1.1±0.1*</td>
<td>0.9±0.1</td>
<td>0.6±0.1*</td>
</tr>
<tr>
<td>Ceramide, ng/mg liver</td>
<td>66±6</td>
<td>53±5*</td>
<td>72±8</td>
<td>82±9*</td>
</tr>
<tr>
<td><strong>High-fat diet</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cholesterol, μg/mg liver</td>
<td>3.0±0.7</td>
<td>3.3±0.4</td>
<td>3.0±0.6</td>
<td>2.7±0.3</td>
</tr>
<tr>
<td>Phospholipids, μg/mg liver</td>
<td>5.1±0.3</td>
<td>5.3±0.6</td>
<td>5.4±0.5</td>
<td>5.1±0.2</td>
</tr>
<tr>
<td>Triglyceride, μg/mg liver</td>
<td>25±5</td>
<td>38±8*</td>
<td>21±4</td>
<td>11±3*</td>
</tr>
<tr>
<td>FFA, μmol/mg liver</td>
<td>11.4±1.8</td>
<td>14.1±2.0*</td>
<td>12.0±2.5</td>
<td>9.2±2.1*</td>
</tr>
<tr>
<td>Sphingomyelin, μg/mg liver</td>
<td>1.5±0.3</td>
<td>2.0±0.2*</td>
<td>1.6±0.3</td>
<td>1.2±0.2*</td>
</tr>
<tr>
<td>Ceramide, ng/mg liver</td>
<td>80±7</td>
<td>59±5*</td>
<td>82±4</td>
<td>95±6*</td>
</tr>
</tbody>
</table>

Values are mean±SD (n=5). FFA indicates free fatty acids; KO, knockout; LTg, liver-specific transgenic; SMS2, Sphingomyelin synthase 2; and WT, wild-type. *P<0.05.

Results

Lipid Analysis in Sms2 Liver-Specific Transgenic and Sms2 KO Mice on Chow Diet

We used LC/MS/MS to measure liver sphingolipids and used enzymatic assay to measure liver total cholesterol, total phospholipid, triglyceride, and free fatty acid. As indicated in Table 1, livers from Sms2 liver-specific transgenic (LTg) mice contained significantly more sphingomyelin and less ceramide than controls (38% and 20%; P<0.01 and P<0.05, respectively), and livers from Sms2 KO mice contained significantly less sphingomyelin and more ceramide levels than controls (33% and 14%; P<0.01 and P<0.05, respectively). We also observed that liver-free fatty acid levels were significantly increased in Sms2LTg (20%; P<0.05) and significantly decreased in Sms2 KO mice (18%; P<0.05). Triglyceride levels were significantly increased in Sms2LTg mice (50%; P<0.01) compared with controls. There was a decrease of triglyceride in Sms2 KO liver, but it was not statistically significant. There were no significant changes in total phospholipids and total cholesterol. All other liver sphingolipids have no noticeable difference (Table I in the online-only Data Supplement).

We next stained the liver section from Sms2LTg and control mice with Oil Red O and found that Sms2 overexpression in the liver promoted lipid accumulation (Figure 1A and 1B; Figure IA–ID in the online-only Data Supplement). We performed insulin tolerance test on Sms2LTg and control mice and found that Sms2LTg mice, with lower liver ceramide levels, have lower insulin sensitivity (Figure II in the online-only Data Supplement) than controls. Similarly, we previously reported that Sms2-deficient mice have higher insulin sensitivity.

Liver Sms2 Overexpression Promotes, Whereas Liver Sms2 Deficiency Diminishes Diet-Induced Steatosis in Mice

We found that Sms2LTg mice had significantly larger livers (Figure 1C and 1D), whereas Sms2 KO mice had smaller livers (Figure 1E and 1F), compared with their respective controls, after 8-week high-fat, high-cholesterol diet feeding. We also noticed that Sms2LTg liver had a milk-like color (Figure 1C).

We further stained the liver frozen sections with Oil Red O, finding that Sms2 overexpression caused substantial lipid accumulation in the liver (Figure 1G and 1H; Figure IE–IH in the online-only Data Supplement), whereas Sms2 deficiency had the opposite results (Figure II and 1J; Figure III in the online-only Data Supplement).

As indicated in Table 1, after a high-fat feeding, the liver from Sms2LTg mice contained significantly higher sphingomyelin levels (33%; P<0.01), whereas the liver from Sms2 KO mice contained significantly less sphingomyelin levels (25%; P<0.01) compared with controls. Liver triglyceride levels were significantly increased in Sms2LTg mice (52%; P<0.001) and significantly decreased in Sms2 KO mice (48%; P<0.001). Liver-free fatty acid levels were significantly increased in Sms2LTg mice (24%; P<0.05) and significantly decreased in Sms2 KO mice (23%; P<0.05). There were no significant changes in total phospholipids and total cholesterol (Table 1).
We have already characterized high-density lipoprotein and apolipoprotein A-I levels in Sms2LTg and Sms2 KO mice. We did not observe changes in high-density lipoprotein cholesterol and apolipoprotein A-I. We also measured ABCA1 levels on mouse liver homogenates using Western blot, and we did not find significant changes (Figure IV in the online-only Data Supplement).

**Ceramide But Not Sphingomyelin or Phosphatidylethanolamine Can Suppress PPARγ2 Expression**

To gain insight into the mechanisms of how Sms2 overexpression promotes and deficiency prevents the formation of fatty livers, we examined the expression levels of the responsible genes using real-time quantitative polymerase chain reaction in the liver. We found that PPARγ2 was significantly elevated in high-fat–fed Sms2 transgenic mice (2.1-fold; P<0.001) but suppressed in Sms2 KO mice (69%; P<0.001; Table 3). Consequently, Cd36 and Fsp27, 2 downstream effectors of PPARγ2, were dramatically increased in Sms2 transgenic mice (3.7-fold, P<0.0001 and 5.8-fold, P<0.0001) and decreased in Sms2 KO mice (48%; P<0.0001 and 61%, P<0.0001; Table 3). We also found that diacylglycerol acyltransferase 1 and diacylglycerol acyltransferase 2 were significantly increased in Sms2 transgenic liver (Table 3). All other genes related to lipid metabolism had no statistically significant changes under Sms2 overexpression and deficiency (Table 3). Our observation suggested that PPARγ2 is at least one of the key factors mediating SMS2 activity–related liver steatosis.

We next sought to examine protein levels of CD36 in Sms2LTg and Sms2 KO livers. We found that Sms2LTg liver had significantly higher CD36 protein levels (7-fold, P<0.001; Figure 2A), whereas Sms2 KO liver had significantly lower CD36 protein levels (70%, P<0.01; Figure 2B) compared with their controls.

CD36 is located on plasma membrane lipid rafts. We then investigated how Sms2 overexpression or deficiency affected CD36 in lipid rafts. We isolated these rafts from the whole liver using reported protocols. CD36 was found in light fractions enriched with the raft markers, Src kinase lyn and caveolin-1 (Figure 2C). We pooled raft fractions (3–5) and nonraft fractions (10–12) to perform a CD36 Western blot. Sms2LTg liver raft regions contained significantly more CD36 (5-fold, P<0.001; Figure 2D), whereas Sms2 KO liver raft regions contained significantly less CD36 (72%, P<0.001; Figure 2E).

To further evaluate the effect of Sms2 liver overexpression or deficiency on CD36, we examined the free fatty acid uptake. Hepatocytes from Sms2LTg or Sms2 KO mice were isolated and incubated with [14C]oleic acid. We found that Sms2LTg hepatocytes took up more free fatty acid (Figure 2F), whereas Sms2 KO hepatocytes took up less (Figure 2G) compared with their controls.

We noticed that Sms2 overexpression decreases ceramide and increases sphingomyelin in the liver homogenates, whereas Sms2 deficiency has opposite effects (Table 1). To directly examine the effect of lipid changes on PPARγ2, we examined whether exogenous ceramide supplementation to...
Huh7 cells, a hepatoma cell line, could stimulate PPARγ2 suppression. For this, we treated the cells with ceramide (10 μmol/L). As shown in Figure 3A–3C, the exogenous supplementation of ceramide in culture significantly reduced PPARγ2, Cd36, and Fsp27 mRNA levels. We also performed PPARγ2 Western blot and found that the protein levels of PPARγ2 were suppressed in a dose-dependent manner (Figure 3D and 3E). We used the same concentration of sphingomyelin and phosphatidylcholine to treat Huh7 cells, but no significant changes were found in terms of PPARγ2 protein levels (Figure 3D and 3E). Furthermore, we found that ceramide 24:0 and 24:0 but not 16:0 are suppressors of PPARγ2 expression (Figure 3F and 3G).

To confirm the suppression effect of ceramide on PPARγ, we performed PPARγ reporter assay and found that ceramide but not sphingomyelin and phosphatidylcholine decreased luciferase activity (Figure 3H). Furthermore, we found that ceramide 24:0 but not 16:0 reduced luciferase activity in a dose-dependent manner (Figure 3I). These results demonstrated that ceramide can suppress PPARγ activity. Furthermore, we treated Sms2LTg mice with PPARγ antagonist (GW9662, 4 mg/kg by intraperitoneal injection) for 4 weeks and found that triglyceride accumulation was significantly reduced compared with vehicle treatment (30%, P<0.05; Figure V in the online-only Data Supplement), suggesting that PPARγ is one of the factors for liver steatosis.

**Discussion**

SMS2 is the major SMS isoform in the liver. It contributes to >70% of the total SMS activity in liver.2 In this study, we demonstrated that (1) Sms2 overexpression decreases hepatic ceramide and increases sphingomyelin levels, whereas Sms2 deficiency has an opposite effect; (2) Sms2 overexpression increases, whereas Sms2 deficiency decreases liver plasma sphingomyelin levels; (3) liver Sms2 overexpression promotes, whereas Sms2 deficiency prevents high-fat diet–induced triglyceride and free fatty acid accumulation in the liver; (4) Sms2 overexpression induces the levels of hepatic PPARγ2 and its downstream genes, Cd36 and Fsp27, whereas Sms2 deficiency reduces all these levels; (5) exogenous ceramide but not sphingomyelin or phosphatidylcholine suppresses PPARγ2, Cd36, and Fsp27 expression levels; and (6) PPARγ antagonist reduces triglyceride accumulation in mouse liver.

There is a relationship between sphingolipid de novo biosynthesis and hepatic steatosis.7 Pharmacological inhibition of serine palmitoyltransferase23 or glucosylceramide synthase26 or the genetic depletion of acid sphingomyelinase27 reduces hepatic triglyceride levels in mice susceptible to the development of a fatty liver. However, the mechanism is still unknown, and sometimes the results are incongruous. Previously, Mitsutake et al28 have reported that Sms2 deficiency in mice diminishes the development of obesity and fatty liver, and they attributed this phenomenon to the reduction of sphingomyelin levels of PPARγ in mice susceptible to the development of a fatty liver.
levels in cell membrane lipid rafts. We also reported that Sms2 deficiency–mediated reduction of plasma membrane sphingomyelin increases insulin sensitivity and decreases high-fat–induced obesity. It is known that sphingomyelin levels in plasma membrane lipid rafts are important in mediating many important cell functions, such as insulin signaling, cholesterol efflux, inflammatory responses, and lipid uptake and transportation. Plasma membrane sphingomyelin-mediated effect is still observed in this study. In this study, we showed that Sms2LTg liver plasma membrane contained significantly more sphingomyelin (Table 2) and significantly more amount of CD36 (Figure 2D) whereas Sms2 KO liver plasma membrane contained significantly less sphingomyelin (Table 2) and CD36 (Figure 2E).

However, there is 1 thing which could not be fully explained by lipid raft sphingomyelin changes: why do Sms2LTg livers have significantly higher and Sms2-deficient livers have significantly lower CD36 and FSP27, a well-known protein involved in hepatocyte lipid droplet formation and liver steatosis, mRNA levels (Table 3)? There must be an upstream mechanism that can upregulate both CD36 and FSP27 expression. Although Mitsutake et al had indicated that PPARγ, which is upstream of CD36 and FSP27, was decreased in Sms2-deficient mouse livers, they did not show why and how PPARγ was regulated under such conditions.

Does ceramide play an important role in mediating liver steatosis? Previous researchers have reported that high ceramide levels contribute to the development of nonalcoholic fatty liver disease via multiple ways involved in insulin resistance, oxidative stress, inflammation, and apoptosis. Yetukuri et al even demonstrated that in ob/ob mice hepatic ceramide levels were strongly correlated with the degree of steatosis. However, what we found in this study was different from the study reported by Yetukuri et al. First of all, we showed that although Sms2 overexpression or deficiency does not change ceramide levels on liver plasma membrane (Table 2), Sms2LTg mice had significantly lower, whereas Sms2 KO mice had higher ceramide levels in liver homogenates (Table 1). The former had severe liver steatosis with (Figure 1G and 1H; Figure IE–IH in the online-only Data Supplement) or without high-fat diet feeding (Figure 1A and 1B; Figure IA–ID in the online-only Data Supplement), whereas the latter had much less liver steatosis (Figure 1I and 1J; Figure I(I)–IL in the online-only Data Supplement). It is plausible that ceramide depletion in the liver causes steatosis, whereas ceramide accumulation has an opposite effect. Second, exogenous ceramide suppressed PPARγ2 in a dose-dependent fashion (Figure 3D and 3E). We further confirmed this by using PPARγ reporter analysis (Figure 3H). Third, it has been reported that, in primary
cultured adipocytes, ceramide treatment reduced PPARγ expression in a time- and concentration-dependent manner. It has also been reported that, in murine mesenchymal stem cells, ceramide treatment reduced PPARγ expression and reduced levels of both triglyceride and specific fatty acids. Recently, we reported that ceramide does not cause cardiac toxicity and insulin resistance. As one of the potential mechanisms, we believe that ceramide can reduce liver steatosis through the direct suppression of PPARγ expression in the liver. Although the role of PPARγ in liver steatosis is still uncertain, our PPARγ antagonist study (Figure V in the online-only Data Supplement) suggests PPARγ is one of the factors for liver steatosis.

In line with the association between low ceramide levels and nonalcoholic fatty liver disease observed in our Sm2Ltg mice, Deevska et al reported that sphingomyelinase (which hydrolyzes sphingomyelin and produce ceramide) deficiency reduced hepatic steatosis and improved insulin sensitivity. Bijl et al reported that glucosylceramide synthase (which uses ceramide to produce glucosylceramide) inhibition markedly reduced liver steatosis in mice. The linkage may be that ceramide can suppress PPARγ expression in the liver (Figure 3). Although PPARγ was once considered an orphan receptor, native and modified polyunsaturated fatty acids have emerged as strong candidates for endogenous activators of this receptor. However, so far no endogenous suppressors of PPARγ have been reported. We hypothesized that certain species of ceramide could be native lipid suppressors for PPARγ. Our results indicated that ceramide 22:0 and 24:0 but not 16:0 can suppress PPARγ in an Huh7 cell culture system (Figure 3F, 3G, and 3I). The detailed mechanism that causes this deserves further investigation.

Another possible mechanism linking SMS2 activity and nonalcoholic fatty liver disease might be related to cellular...
sphingomyelin levels. We have previously reported that Sms2 deficiency–mediated reduction of sphingomyelin in the plasma membranes leads to an improvement in tissue and whole-body insulin sensitivity, and this might be associated with less liver steatosis in these mice. However, exogenous sphingomyelin had no effect on PPARγ expression (Figure 3).

The importance of this study is the finding that increase in ceramide levels can prevent liver steatosis through suppression of PPARγ. Increasing ceramide levels in the liver can be achieved by SMS2 inhibition.

Acknowledgments

We thank Drs David Peake, Hai H. Bui, and Youyan Zhang (Eli Lilly) for their valued support and technical guidance.

Sources of Funding

This work was supported by National Institutes of Health grants HL69817 and VA Merit 000900-01.

Disclosures

None.

References


37. Ables GP. Update on ppargamma and nonalcoholic fatty liver disease. PPAR Res. 2012;2012:912351.


**Significance**

Imbalances in input, oxidation, synthesis, and output of fatty acids could contribute to nonalcoholic fatty liver disease. There is a relationship between sphingolipid de novo biosynthesis and nonalcoholic fatty liver disease. Sphingomyelin synthase overexpression reduces liver ceramide level, thus inducing liver steatosis, whereas sphingomyelin synthase 2 deficiency has opposite effect. The current study is the first one to indicate that ceramide can suppress proliferator-activated receptor γ2 and its target genes, CD36 and FSP27, thus diminishing liver steatosis. Regulation of ceramide levels through manipulation of sphingomyelin synthase activity could have a clinical impact on the treatment of nonalcoholic fatty liver disease.
Sphingomyelin Synthase 2 Activity and Liver Steatosis: An Effect of Ceramide-Mediated Peroxisome Proliferator-Activated Receptor γ2 Suppression

Yue Li, Jibin Dong, Tingbo Ding, Ming-Shang Kuo, Guoqing Cao, Xian-Cheng Jiang and Zhiqiang Li

Arterioscler Thromb Vasc Biol. 2013;33:1513-1520; originally published online May 2, 2013; doi: 10.1161/ATVBAHA.113.301498

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/33/7/1513

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2013/05/02/ATVBAHA.113.301498.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Materials and Methods

Mice and diet. SMSLTg and SMS KO mice were created in our laboratory. The SMS2LTg founder animals, with C57BL/6J/CBA mixed background, were backcrossed with C57BL/6J mice five generations. The original SMS2 KO mice, with 129 mouse genetic background, were backcrossed with C57BL/6 mice six generations. All mice used were littermates, or with the same genetic background. The groups of mice (male or female at age 10 weeks) were fed either rodent chow, or a high-fat and high-cholesterol (Research Diets, Inc.) diet for 8 weeks. All procedures and protocols involving the use of animals were approved by the SUNY Downstate Medical Center Animal Care and Use Committee.

Liver lipid measurements. Total liver lipids were extracted according to a modified method from Folch et al. Briefly, snap-frozen liver tissues (∼100 mg) were homogenized in 5 ml of 1 N NaOH and extracted twice with 5–10 ml of a chloroform/methanol (2:1, v/v) solution. The organic layer was dried under nitrogen gas and resolubilized in 1 ml of chloroform containing 2% Triton X-100. This extract was dried again and resuspended in 1 ml of water to achieve a final concentration of 2% Triton X-100, and then measured triglyceride concentration using kit from Thermo, measured free fatty acids, total cholesterol, and total phospholipid concentration using kits from Wako.

Histological analysis. Liver tissue samples were either embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek) and sectioned (7 μm) for neutral lipid staining using Oil Red O and a hematoxylin counterstain or fixed in 10% formalin,
embedded in paraffin, and sectioned (5 μm) for hematoxylin and eosin staining. Sections were photographed at either ×100 (hematoxylin and eosin) or ×200 (Oil Red O) magnification.

**Lipid analyses by LC MS/MS.** Ceramides comprised of a D-erythro-sphingosine backbone and a fatty acid amide were determined by a 2D LC-ESI MS/MS method. Lipid extracts from cells were injected onto a normal-phase column, where the polar lipids were retained, while the ceramide fractions were trapped on a reversed-phase column. Ceramides were eluted, separated, and detected using a triple quadrupole mass spectrometer equipped with positive ion electrospray ionization (ESI) and selected reaction monitoring. Levels of PC and SM were measured via a flow injection ESI-MS/MS method. Protonated molecular ions of PC/SM species are selected by precursor ion scans of m/z 184 and the ion intensities across the flow injection profile were summed together, and after isotope correction, the quantities of each PC and SM species are then calculated relative to PC and SM internal standards.

**mRNA analyses.** RNA was isolated from cells using TriZol (Invitrogen). The mouse primers used for SMS2 RT-PCR were: Forward 5’-GGTTCCACAGAAACCAAGA-3’, and reverse 5’- GATGCCTGTTTTCCACCACT-3’. For liver SMS2 transgene, human SMS2 mRNA was determined by real-time PCR using Taqman® Gene Expression Assay (Applied Biosystems, assay ID Hs00380453_m1). The human primers used for SMS2 were: Forward 5’- TCCAGTGTGCTCCAAAGCTC-3’ and reverse 5’- CACTCAGCAGCCAGCGACT-3’. 18S rRNA was used as internal control. The forward
and reverse primer sequences for 18S rRNA are: 5’-AGTCCCTGCCCTTTGTACACA-3’ and 5’-GATCCGAGGGCCTCACTAAAC-3’, respectively.

**SMS activity assay.** Cells were homogenized in a buffer containing 50 mM Tris-HCl, 1 mM EDTA, 5% sucrose, and a cocktail of protease inhibitors (Sigma). The homogenate was centrifuged at 5000 rpm for 10 minutes and the supernatant was mixed in assay buffer containing 50 mM Tris-HCl (pH 7.4), 25 mM KCl, C₆-NBD-ceramide (3.3 μg/ml), and phosphotidylcholine (100 μg/ml). The mixture was incubated at 37°C for 2 hours. Lipids were extracted in chloroform: methanol (2:1, v/v), dried under N₂ gas, and separated by thin layer chromatography (TLC) Chloroform:MeOH:20% NH₄OH (14:6:1, v/v). Band intensity was quantified by Image–Pro Plus 4.5 (Media Cybernetics Inc.).

**Plasma membrane isolation.** Mouse liver (0.5 g) was homogenized and plasma membrane was isolated using a kit (Biovision). The purity of the preparation was checked by Western blot, using the cytoplasmic, total membrane, and plasma membrane fractions, with respective antibodies as we did previously.

**Lipid raft isolation.** Liver lipid rafts were isolated, using reported protocols. Briefly, 0.1 g mouse liver was homogenized in 1.5 ml of 0.5 M Na₂CO₃ (pH 11), containing protease inhibitors. The homogenates were centrifuged (1,300 g, 5 minutes) to pellet cellular debris and nuclei. One milliliter of the postnuclear supernatant was then adjusted to 45% sucrose by addition of 1 ml of 90% sucrose, 50 mM Hepes (pH 6.5), and 150 mM NaCl. A discontinuous sucrose gradient was formed by overlaying this solution with 6 ml of
35% sucrose and 3.5 ml of 5% sucrose, both in the same buffer, containing 0.25 M Na₂CO₃, and this was centrifuged at 38,000 rpm for 18 hours in a SW41 rotor (Beckman). Fractions from top to bottom (1 ml each) were collected. Lyn kinase and caveolin-1 were used to locate the raft fractions.

**Free fatty acid uptake.** Mouse hepatocytes were isolated from the liver according our reported procedure. Liver fatty acid uptake was assayed according to reported method with modification. Briefly, viable hepatocytes were identified by trypan blue exclusion and counted, and incubated for 3 h in DMEM containing 10% fetal bovine serum (FBS), 1% penicillin–streptomycin mix and 1% L-glutamine. The cells were washed once with PBS, and then incubated in 1 ml of assay buffer (40 µM sodium oleate, 10 µM fatty acid-free bovine serum albumin, 5 µCi/ml [14C]oleate in phosphate-buffered saline (PBS) with 1 mM MgCl₂ and 1.2 mM CaCl₂) for 2 and 5 min at 37 °C. Assays were stopped by the addition of 1 ml of ice-cold stop solution (PBS containing 1 mM MgCl₂, 1.2 mM CaCl₂, 0.1% fatty acid-free bovine serum albumin, and 500 µM phloretin). The cells were washed three times with the above stop solution, and then lipids were extracted using Hexanes/Isopropanol (3/2, v/v). Radioactivity was analyzed by scintillation counting.

**Exogenous ceramide, sphingomyelin, and phosphatidylcholine supplementation.**
Sphingomyelin (Sigma) and phosphatidylcholine (Sigma) were dissolved in absolute ethanol. Ceramde was dissolved in ethanol/dodecan (99.8/0.2, v/v) to make a 2-mM stock. Huh7 cells were incubated with exogenous 0, 10, and 30 µM sphingomyelin, ceramide or phosphatidylcholine for 24 h.
**Statistical analysis.** Each experiment was conducted at least 3 times. Unless otherwise indicated, data are expressed as mean ± SD. Differences between 2 groups were analyzed by unpaired 2-tailed Student’s *t* test and among multiple groups by ANOVA followed by Student-Newman-Keuls test. A *P* value of less than 0.05 was considered significant.
Supplement

Supplemental figure legends:

**Supplemental Fig. I. The effect of SMS2 overexpression and deficiency on liver lipid accumulation.** Liver samples were embedded in Tissue-Tek optimal cutting temperature compound (Sakura Finetek), frozen, and sectioned (7 μm), then were stained Oil Red O and hematoxylin. Sections were photographed at x100 and x250 magnification. Panel A-D, livers from control and SMS2 Tg mice on chow. Panel E-H, livers from control and SMS2 Tg mice on a high fat high cholesterol diet. Panel I-L, mouse livers from control and SMS2 KO mice on a high fat high cholesterol diet. This set of result is the representatives of 6 WT and 6 SMS2LTg mice, and 6 WT and 6 SMS2 KO mice.

**Supplemental Fig. II. Insulin tolerance test.** Mice were fasted for 15 h, insulin (0.75 units per kg of body weight) was injected via i.p. and then blood glucose levels were measured immediately before and 15, 30, and 60 min after insulin injection. Values are Mean ± S.E., n = 9, *P<0.05.

**Supplemental Fig. III. Liver plasma membrane purity determination.** Plasma membrane isolation from mouse liver. The purity of cytoplasm (Cyto), total subcellular organelle membranes (TM), and plasma membranes (PM) were determined by Western blot. Na⁺/K⁺ATPase is plasma membrane marker and Cytochrome C is mitochondrial marker.
**Supplemental Fig. IV. Liver ABCA1 Western blotting.** SDS-PAGE was performed on 4–15% SDS-polyacrylamide gradient gel using mouse liver homogenate, and the separated proteins were transferred to nitrocellulose membrane. Western blot analysis for ABCA1 was performed. Values are Mean ± S.E., N=3.

**Supplemental Fig. V. PPAR-γ antagonist GW9662 ameliorate liver steatosis.** PPARγ antagonist GW9662 was injected into SMS2 Tg mice (i.p., 2 mg/kg body weight per day) for four weeks, and then the mice were sacrificed and the liver triglyceride was measured. N=5, *P <0.05.

**Supplemental Table I. Liver lipid measurement in SMS2 KO, SMS2LTg, and WT mice.**

<table>
<thead>
<tr>
<th>Mice</th>
<th>Sph (ng/mg liver)</th>
<th>S-1-P (ng/mg liver)</th>
<th>DHS-1-P (ng/mg liver)</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>1.9±0.2</td>
<td>0.15±0.03</td>
<td>0.18±0.01</td>
</tr>
<tr>
<td>SMS2 KO</td>
<td>2.1±0.3</td>
<td>0.16±0.02</td>
<td>0.17±0.02</td>
</tr>
<tr>
<td>WT</td>
<td>1.7±0.3</td>
<td>0.13±0.03</td>
<td>0.19±0.02</td>
</tr>
<tr>
<td>SMS2LTg</td>
<td>1.8±0.1</td>
<td>0.15±0.02</td>
<td>0.17±0.03</td>
</tr>
</tbody>
</table>

Value: mean±SD; n=4-5. Sph, sphingosine; S-1-P, sphingosine-1-phosphate; DHS-1-P, dihydroxyl-sphingosine-1-phosphate.
Supplemental Fig. I. Li et al.
Supplemental Fig. III. Li et al.
Supplemental Fig. VI. Li et al.

**Western Blot Image**

- **WT**
- **SMS2 Tg**

**ABCA1**

**β-actin**

**Bar Graph**

Liver ABCA1 levels (% of WT)

- **WT**
- **SMS2 Tg**
Liver TG

Supplemental Fig. V. Li et al.

Liver triglyceride (µg/mg tissue)

SMS2 Tg control  SMS2 Tg GW9662 Treatment

*